On Monday, Pyxis Oncology Inc (NASDAQ: PYXS) opened higher 3.73% from the last session, before settling in for the closing price of $1.34. Price fluctuations for PYXS have ranged from $0.83 to $5.39 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -74.92% annually for the last half of the decade. Company’s average yearly earnings per share was noted 1.26% at the time writing. With a float of $44.14 million, this company’s outstanding shares have now reached $62.02 million.
In an organization with 44 employees, it is important to assess its efficiency.
Pyxis Oncology Inc (PYXS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Pyxis Oncology Inc is 28.82%, while institutional ownership is 33.02%. The most recent insider transaction that took place on Apr 21 ’25, was worth 14,362. Before that another transaction happened on Apr 17 ’25, when Company’s Director proposed sale 200 for $0.97, making the entire transaction worth $194.
Pyxis Oncology Inc (PYXS) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.35 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.31) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.41% during the next five years compared to -74.92% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Check out the current performance indicators for Pyxis Oncology Inc (PYXS). In the past quarter, the stock posted a quick ratio of 5.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.59, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.16 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.93 million. That was better than the volume of 0.55 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 87.16%.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 93.30%, which indicates a significant increase from 91.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0907 in the past 14 days, which was higher than the 0.0882 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1671, while its 200-day Moving Average is $1.4605. However, in the short run, Pyxis Oncology Inc’s stock first resistance to watch stands at $1.4233. Second resistance stands at $1.4567. The third major resistance level sits at $1.5133. If the price goes on to break the first support level at $1.3333, it is likely to go to the next support level at $1.2767. The third support level lies at $1.2433 if the price breaches the second support level.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
There are currently 62,018K shares outstanding in the company with a market cap of 86.21 million. Presently, the company’s annual sales total 16,150 K according to its annual income of -77,330 K. Last quarter, the company’s sales amounted to 2,820 K and its income totaled -18,350 K.
